Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Neurological Sciences
Published in: Neurological Sciences 3/2019

01-03-2019 | Original Article

Decreased serum orexin A levels in drug-naive children with attention deficit and hyperactivity disorder

Authors: Saliha Baykal, Yakup Albayrak, Ferit Durankuş, Savaş Güzel, Özlem Abbak, Nihan Potas, Murat Beyazyüz, Koray Karabekiroğlu, Mustafa Metin Donma

Published in: Neurological Sciences | Issue 3/2019

Login to get access

Abstract

Attention deficit/hyperactivity disorder (ADHD) is one of the most common psychiatric disorders of childhood and characterized by inattention, hyperactivity, and impulsivity. ADHD is a neurodevelopmental disorder, and its etiology has not yet been determined precisely. Orexin A is thought to play an important role in different forms of learning, memory, and attention. Despite its importance in attention and learning, no study has investigated serum orexin levels in patients with ADHD. In the present study, we aimed to compare serum orexigenic neuropeptides such as orexin A and orexin B, neuropeptide Y, and ghrelin between drug naive children with ADHD and healthy children. Fifty-six drug-naive children with ADHD and 40 healthy controls were enrolled in the study. After comparison of serum orexin A and orexin B, neuropeptide Y, and ghrelin, we found that serum orexin A levels were significantly lower in the ADHD group (p = 0.001). Furthermore, serum orexin A levels were compared between ADHD subgroups. Orexin A levels were significantly lower in the inattentive subtype compared with the hyperactive subtype and combined subtype (p = 0.009). Our results indicate that orexin A might be a neurobiological etiological factor in ADHD, particularly associated with attention symptoms. The present study is the first to demonstrate decreased serum orexin A levels in drug-naive children with ADHD. Further studies are needed to confirm our results and to show the effects of treatments involving orexin A in patients with ADHD.
Literature
1.
American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders (5th ed). American Psychiatric Publishing, Arlington
2.
3.
Pliszka SR (2015) Conceptual issues in understanding comorbidity in ADHD. In: Adler LA, Spencer TJ, Wilens TE (eds) Attention-deficit hyperactivity disorder in adults and children, 1st edn. Cambridge University Press, UK, pp 63–72CrossRef
4.
5.
6.
Quarta D, Smolders I (2014) Rewarding, reinforcing and incentive salient events involve orexigenic hypothalamic neuropeptides regulating mesolimbic dopaminergic neurotransmission. Eur J Pharm Sci 57:2–10CrossRefPubMed
7.
Kastin AJ, Akerstrom V (1999) Nonsaturable entry of neuropeptide Y into brain. Am J Phys:E479–E482
8.
De la Herrán-Arita AK, Guerra-Crespo M, Drucker-Colín R (2011) Narcolepsy and orexins: an example of progress in sleep research. Front Neurol 2:26PubMedPubMedCentral
9.
Uriarte M, De Francesco PN, Fernandez G, Cabral A, Castrogiovanni D, Lalonde T, Luyt LG, Trejo S, Perello M (2018) Evidence supporting a role for the blood-cerebrospinal fluid barrier transporting circulating ghrelin into the brain. Mol Neurobiol. https://​doi.​org/​10.​1007/​s12035-018-1362-8
10.
Cortese S, Konofal E, Lecendreux M (2008) Alertness and feeding behaviors in ADHD: does the hypocretin/orexin system play a role? Med Hypotheses 71(5):770–775CrossRefPubMed
11.
Li SB, Jones JR, de Lecea L (2016) Hypocretins, neural systems, physiology, and psychiatric disorders. Curr Psychiatry Rep 18(1):7CrossRefPubMed
12.
Faraone SV (2018) The pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev 87:255–270CrossRefPubMedPubMedCentral
13.
Achenbach TM, Edelbrock C (1983) Manual for the child behavior checklist and revised child behavior profile. Queen City Printers, Burlington
14.
Kaufman J, Birmaher B, Brent D (1997) Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (KSADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980–988CrossRefPubMed
15.
16.
Cook EH Jr, Stein MA, Krasowski MD, Cox NJ, Olkon DM, Kieffer JE, Leventhal BL (1995) Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet 56:993–998PubMedPubMedCentral
17.
Madras BK, Miller GM, Fischman AJ (2005) The dopamine transporter and attention-deficit/hyperactivity disorder. Biol Psychiatry 57:1397–1409CrossRefPubMed
18.
VanNess SH, Owens MJ, Kilts CD (2005) The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density. BMC Genet 6(55):55CrossRefPubMedPubMedCentral
19.
Borodovitsyna O, Flamini M, Chandler D (2017) Noradrenergic modulation of cognition in health and disease. Neural Plast 2017:6031478
20.
Zajo KN, Fadel JR, Burk JA (2016) Orexin A-induced enhancement of attentional processing in rats: role of basal forebrain neurons. Psychopharmacology 233(4):639–647CrossRefPubMed
21.
22.
Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, Arch JRS, Buckingham RE, Haynes AC, Carr SA, Annan RS, McNulty DE, Liu WS, Terrett JA, Elshourbagy NA, Bergsma DJ, Yanagisawa M (1998) Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92:573–585CrossRefPubMed
23.
Ritchie C, Okuro M, Kanbayashi T, Nishino S (2010) Hypocretin ligand deficiency in narcolepsy: recent basic and clinical insights. Curr Neurol Neurosci Rep 10:180–189CrossRefPubMed
24.
Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, Cornford M, Siegel JM (2000) Reduced number of hypocretin neurons in human narcolepsy. Neuron 27:469–474CrossRefPubMedPubMedCentral
25.
Arrigoni E, Mochizuki T, Scammell TE (2010) Activation of the basal forebrain by the orexin/hypocretin neurones. Acta Physiol (Oxf) 198:223–235CrossRef
26.
Fadel J, Burk JA (2010) Orexin/hypocretin modulation of the basal forebrain cholinergic system: role in attention. Brain Res 1314:112–123CrossRefPubMed
27.
Boschen KE, Fadel JR, Burk JA (2009) Systemic and intrabasalis administration of the orexin-1 receptor antagonist, SB-334867, disrupts attentional performance in rats. Psychopharmacology (Berlin) 206:205–213CrossRef
28.
29.
Fronczek R, van Geest S, Frolich M, Overeem S, Roelandse FW, Lammers GJ, Swaab DF (2012) Hypocretin (orexin) loss in Alzheimer’s disease. Neurobiol Aging 33:1642–1650CrossRefPubMed
30.
Slats D, Claassen JA, Lammers GJ, Melis RJ, Verbeek MM, Overseem S (2012) Association between hypocretin-1 and amyloid-β42 cerebrospinal fluid levels in Alzheimer’s disease and healthy controls. Curr Alzheimer Res 9:1119–1125CrossRefPubMed
31.
Wennstrom M, Londos E, Minthon L, Nielsen HM (2012) Altered CSF orexin and α-synuclein levels in dementia patients. J Alzheimers Dis 29:125–132CrossRefPubMed
32.
Deadwyler SA, Porrino L, Siegel JM, Hampson RE (2007) Systemic and nasal delivery of orexin-A (hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci 27:14239–14247CrossRefPubMedPubMedCentral
33.
Akbari E, Naghdi N, Motamedi F (2007) The selective orexin 1 receptor antagonist SB-334867-A impairs acquisition and consolidation but not retrieval of spatial memory in Morris water maze. Peptides 28:650–656CrossRefPubMed
34.
Aou S, Li XL, Li AJ, Oomura Y, Shiraishi T, Sasaki K, Imamura T, Wayner MJ (2003) Orexin-A (hypocretin-1) impairs Morris water maze performance and CA1-Schaffer collateral long-term potentiation in rats. Neuroscience 119:1221–1228CrossRefPubMed
35.
Jaeger LB, Farr SB, Banks WA, Morley JE (2002) Effects of orexin-A on memory processing. Peptides 23:1683–1688CrossRefPubMed
36.
Yang L, Zou B, Xiong X, Pascual C, Xie J, Malik A, Xie J, Sakurai T, Xie XS (2013) Hypocretin/orexin neurons contribute to hippocampus dependent social memory and synaptic plasticity in mice. J Neurosci 33:5275–5284CrossRefPubMedPubMedCentral
37.
Lundberg JM, Terenius L, Hokfelt T et al (1982) Neuropeptide Y (NPY)-like immunoreactivity in peripheral noradrenergic neurons and effect of NPY on sympathetic function. Acta Physiol Scand 116:477–480CrossRefPubMed
38.
Hashimoto K (2010) Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatr Clin Neurosci 64:341–357CrossRef
39.
Lindell SG, Schwandt ML, Sun H, Sparenborg JD, Björk K, Kasckow JW, Sommer WH, Goldman D, Higley JD, Suomi SJ, Heilig M, Barr CS (2010) Functional NPY variation as a factor in stress resilience and alcohol consumption in rhesus macaques. Arch Gen Psychiatry 67:423–431CrossRefPubMedPubMedCentral
40.
Zhu G, Pollak L, Mottagui-Tabar S, Wahlestedt C, Taubman J, Virkkunen M, Goldman D, Heilig M (2003) NPY Leu7Pro and alcohol dependence in Finnish and Swedish populations. Alcohol Clin Exp Res 27:19–24CrossRefPubMed
41.
Heilig M, Zachrisson O, Thorsell A, Ehnvall A, Mottagui-Tabar S, Sjögren M, Åsberg M, Ekman R, Wahlestedt C, Ågren H (2004) Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism. J Psychiatr Res 38:113–121CrossRefPubMed
42.
Oades RD, Daniels R, Rascher W (1998) Plasma neuropeptide-Y levels, monoamine metabolism, electrolyte excretion and drinking behavior in children with attention-deficit hyperactivity disorder. Psychiatry Res 80:177–186CrossRefPubMed
43.
Özcan Ö, Arslan M, Güngör S, Yüksel T, Selimoğlu MA (2018) Plasma leptin, adiponectin, neuropeptide Y levels in drug naive children with ADHD. J Atten Disord 22(9):896–900CrossRefPubMed
44.
Hekim Bozkurt Ö, Güney E, Göker Z, Şenses Dinç G, Alışık M, Erel Ö, Çöp E, Üneri ÖŞ (2018) Neuropeptide Y levels in children and adolescents with attention deficit hyperactivity disorder. Turk Psikiyatri Derg 29(1):31–35PubMed
45.
Colldén G, Tschöp MH, Müller TD (2017) Therapeutic potential of targeting the ghrelin pathway. Int J Mol Sci 18(4):E798
46.
Gurbuz F, Gurbuz BB, Celik GG, Yildirim V, Ucakturk SA, Seydaoglu G, Ucakturk EM, Topaloglu AK, Yuksel B (2016) Effects of methylphenidate on appetite and growth in children diagnosed with attention deficit and hyperactivity disorder. Pediatr Endocrinol Metab 29(1):85–92
47.
Sahin S, Yuce M, Alacam H, Karabekiroglu K, Say GN, Salıs O (2014) Effect of methylphenidate treatment on appetite and levels of leptin, ghrelin, adiponectin, and brain-derived neurotrophic factor in children and adolescents with attention deficit and hyperactivity disorder. Int J Psychiatry Clin Pract 18(4):280–287CrossRefPubMed
48.
Metadata
Title
Decreased serum orexin A levels in drug-naive children with attention deficit and hyperactivity disorder
Authors
Saliha Baykal
Yakup Albayrak
Ferit Durankuş
Savaş Güzel
Özlem Abbak
Nihan Potas
Murat Beyazyüz
Koray Karabekiroğlu
Mustafa Metin Donma
Publication date
01-03-2019
Publisher
Springer International Publishing
Published in
Neurological Sciences / Issue 3/2019
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-018-3692-8

Other articles of this Issue 3/2019

Neurological Sciences 3/2019 Go to the issue

Letter to the Editor

Montreal Cognitive Assessment (MoCA) and its memory tasks for detecting mild cognitive impairment

Review Article

Red Flags for early referral of people with symptoms suggestive of narcolepsy: a report from a national multidisciplinary panel

Letter to the Editor

Acute necrotizing encephalopathy of childhood associated with human herpes virus 6 in Croatia

Letter to the Editor

Task-specific focal chin tremor in idiopathic Parkinson’s disease: is it an isolated phenomenon or a part of parkinsonism?

Original Article

Regression-based normative data and equivalent scores for Trail Making Test (TMT): an updated Italian normative study

Brief Communication

Self-assessment reliability in multiple sclerosis: the role of socio-demographic, clinical, and quality of life aspects